CytoCore Readies e2 Collector for High-Volume Manufacturing.

16-Cavity Mold Able to Produce 800,000 Units/Month by Fourth Quarter

CHICAGO -- CytoCore Inc. (OTCBB:CYCR), a late-stage bio-scientific research company advancing tools and testing for the early detection and diagnosis of deadly reproductive cancers, today announced that it is readying its proprietary e2 Collector[TM] sample retrieval device for high volume manufacturing by late summer.

Concluding a successful manufacturing development process with parts already being produced for and used in CytoCore's ongoing e2 Collector clinical trials, CytoCore has contracted with Applied Technology Products Corporation to begin the tooling process to produce a 16-cavity mold in preparation for high volume manufacturing. ATP will also be developing the assembly processes as the final step leading to volume manufacturing.

"We expect volume production to be ready by mid-summer, capable of producing up to 800,000 units a month by the fourth quarter," said Dr. Augusto Ocana, CEO of CytoCore. "With our cash-flow break-even point at a volume of between 80,000 and 100,000 units per month, we're projecting strong returns right out of the gate."

"The early production and clinical trial usage gives us confidence to begin the manufacturing build-up. We are preparing to deliver a truly high-quality, low-cost medical product. We expect further clinical trial results to confirm the Collector's ability to enhance the quality of cell sampling for Pap and HPV tests. Because this simple product is capable of offering enhanced early detection and diagnosis, it has the potential to save the lives of many women," said Ocana.

CytoCore anticipates the current e2 Collector trials which began last month and the subsequent FDA review to be concluded during the summer. In parallel, the Company expects over the second quarter that it will sign several distribution contracts for the Collector, so that at the conclusion of the FDA review, the Company can begin sales and distribution of the Collector.

The first significant upgrade to the Pap test in 50 years, the e2 Collector is a small disposable balloon device designed to enhance the thoroughness and consistency of cell collections for the Pap smear and HPV test screenings performed annually on some 180 million women worldwide. The e2 Collector is designed to significantly improve both the patient's comfort and physician's confidence in the collection procedure.

The e2 Collector's innovative handle and balloon disposable components offer excellent performance comparison and distinct patient comfort improvement over the brush-and-spatula method currently used by doctors when taking routine Pap samples for the early screening of cervical cancer.

For further information about the e2 Collector and CytoCore's full suite of products for the diagnoses and treatment of reproductive cancers, visit www.CytoCoreInc.com. For further information about cervical cancer, visit the American Cancer Society's webpage: www.cancer.org.

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath[TM] System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath[TM] System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.